Literature DB >> 25351767

Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.

David Quigley1, Laxmi Silwal-Pandit2, Ruth Dannenfelser3, Anita Langerød2, Hans Kristian Moen Vollan4, Charles Vaske5, Josie Ursini Siegel6, Olga Troyanskaya3, Suet-Feung Chin7, Carlos Caldas8, Allan Balmain9, Anne-Lise Børresen-Dale10, Vessela Kristensen11.   

Abstract

UNLABELLED: Lymphocytic infiltration is associated with better prognosis in several epithelial malignancies including breast cancer. The tumor suppressor TP53 is mutated in approximately 30% of breast adenocarcinomas, with varying frequency across molecular subtypes. In this study of 1,420 breast tumors, we tested for interaction between TP53 mutation status and tumor subtype determined by PAM50 and integrative cluster analysis. In integrative cluster 10 (IC10)/basal-like breast cancer, we identify an association between lymphocytic infiltration, determined by an expression score, and retention of wild-type TP53. The expression-derived score agreed with the degree of lymphocytic infiltration assessed by pathologic review, and application of the Nanodissect algorithm was suggestive of this infiltration being primarily of cytotoxic T lymphocytes (CTL). Elevated expression of this CTL signature was associated with longer survival in IC10/Basal-like tumors. These findings identify a new link between the TP53 pathway and the adaptive immune response in estrogen receptor (ER)-negative breast tumors, suggesting a connection between TP53 inactivation and failure of tumor immunosurveillance. IMPLICATIONS: The association of lymphocytic invasion of ER-negative breast tumors with the retention of wild-type TP53 implies a novel protective connection between TP53 function and tumor immunosurveillance. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25351767      PMCID: PMC4465579          DOI: 10.1158/1541-7786.MCR-14-0387

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  38 in total

1.  BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks.

Authors:  Steven Maere; Karel Heymans; Martin Kuiper
Journal:  Bioinformatics       Date:  2005-06-21       Impact factor: 6.937

Review 2.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

3.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

4.  Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.

Authors:  Christine Desmedt; Benjamin Haibe-Kains; Pratyaksha Wirapati; Marc Buyse; Denis Larsimont; Gianluca Bontempi; Mauro Delorenzi; Martine Piccart; Christos Sotiriou
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 5.  Tumour immunity: effector response to tumour and role of the microenvironment.

Authors:  Alberto Mantovani; Pedro Romero; A Karolina Palucka; Francesco M Marincola
Journal:  Lancet       Date:  2008-02-13       Impact factor: 79.321

6.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Authors:  Magali Olivier; Anita Langerød; Patrizia Carrieri; Jonas Bergh; Sigrid Klaar; Jorunn Eyfjord; Charles Theillet; Carmen Rodriguez; Rosette Lidereau; Ivan Bièche; Jennifer Varley; Yves Bignon; Nancy Uhrhammer; Robert Winqvist; Arja Jukkola-Vuorinen; Dieter Niederacher; Shunsuke Kato; Chikashi Ishioka; Pierre Hainaut; Anne-Lise Børresen-Dale
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

7.  Granzyme B-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells.

Authors:  Franck Meslin; Jerome Thiery; Catherine Richon; Abdelali Jalil; Salem Chouaib
Journal:  J Biol Chem       Date:  2007-09-13       Impact factor: 5.157

8.  The humoral immune system has a key prognostic impact in node-negative breast cancer.

Authors:  Marcus Schmidt; Daniel Böhm; Christian von Törne; Eric Steiner; Alexander Puhl; Henryk Pilch; Hans-Anton Lehr; Jan G Hengstler; Heinz Kölbl; Mathias Gehrmann
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

9.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.

Authors:  Andrew E Teschendorff; Ahmad Miremadi; Sarah E Pinder; Ian O Ellis; Carlos Caldas
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

10.  Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Authors:  H R Ali; E Provenzano; S-J Dawson; F M Blows; B Liu; M Shah; H M Earl; C J Poole; L Hiller; J A Dunn; S J Bowden; C Twelves; J M S Bartlett; S M A Mahmoud; E Rakha; I O Ellis; S Liu; D Gao; T O Nielsen; P D P Pharoah; C Caldas
Journal:  Ann Oncol       Date:  2014-06-09       Impact factor: 32.976

View more
  32 in total

1.  Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Authors:  Stefani Spranger; Ayelet Sivan; Leticia Corrales; Thomas F Gajewski
Journal:  Adv Immunol       Date:  2016-01-22       Impact factor: 3.543

Review 2.  Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.

Authors:  Stefani Spranger
Journal:  Int Immunol       Date:  2016-03-17       Impact factor: 4.823

Review 3.  Impact of oncogenic pathways on evasion of antitumour immune responses.

Authors:  Stefani Spranger; Thomas F Gajewski
Journal:  Nat Rev Cancer       Date:  2018-01-12       Impact factor: 60.716

Review 4.  Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.

Authors:  Yamei Chen; Ying Jin; Xiao Hu; Ming Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-08       Impact factor: 4.553

Review 5.  Cancer-associated inflammation: pathophysiology and clinical significance.

Authors:  Piotr Pęczek; Monika Gajda; Kacper Rutkowski; Marta Fudalej; Andrzej Deptała; Anna M Badowska-Kozakiewicz
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-19       Impact factor: 4.322

Review 6.  Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells.

Authors:  David A Quigley; Vessela Kristensen
Journal:  Mol Oncol       Date:  2015-10-23       Impact factor: 6.603

7.  T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Authors:  Jonathan A Trujillo; Randy F Sweis; Riyue Bao; Jason J Luke
Journal:  Cancer Immunol Res       Date:  2018-09       Impact factor: 11.151

8.  The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.

Authors:  Guangyu Wang; Dandan Xu; Zicheng Zhang; Xinhui Li; Jiaqi Shi; Jie Sun; Huan-Zhong Liu; Xiaobo Li; Meng Zhou; Tongsen Zheng
Journal:  NPJ Precis Oncol       Date:  2021-06-22

Review 9.  Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches.

Authors:  Ravi G Gupta; Fenge Li; Jason Roszik; Gregory Lizée
Journal:  Cancer Discov       Date:  2021-03-15       Impact factor: 38.272

Review 10.  Tumor-intrinsic oncogene pathways mediating immune avoidance.

Authors:  Stefani Spranger; Thomas F Gajewski
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.